Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis

Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis (RF-negative polyarticular JIA) is the second most common subtype of JIA, accounting for approximately 20–25% of all JIA cases. It is defined by arthritis affecting five or more joints during the first 6 months of disease, in a child under 16 years of age, with a negative rheumatoid factor on two occasions at least 3 months apart. RF-negative polyarticular JIA is a heterogeneous subtype with a wide spectrum of disease severity, ranging from mild symmetric small joint arthritis to severe erosive polyarthropathy. It predominantly affects females (F:M ratio approximately 3:1), with a bimodal age distribution (peak onset 1–4 years and 10–14 years). Unlike its RF-positive counterpart, RF-negative polyarticular JIA does not consistently have a poor prognosis, and many children achieve sustained remission.

RF-negative polyarticular JIA is a T cell-mediated autoimmune synovitis with prominent TNF-α and IL-6 driven inflammation. Unlike RF-positive disease (which resembles adult RA with anti-CCP and RF autoantibodies), RF-negative polyarticular JIA lacks well-defined autoantibody targets and represents a more heterogeneous immunological entity.

Immunological Mechanisms

• CD4+ T cell infiltration of synovium — Th1 and Th17 pathways drive synovial inflammation; TNF-α, IL-6, and IL-17 are elevated in synovial fluid and drive pannus formation
• Macrophage activation — produces metalloproteinases causing cartilage and bone erosion; activated macrophages contribute to chronic synovitis
• B cell involvement — B cells can produce non-RF autoantibodies; ANA is present in 40–50%, suggesting some B cell dysregulation even without RF
• HLA associations — HLA-DR8 and HLA-DR5 confer susceptibility; HLA-DR4 (adult RA-associated) is uncommon, distinguishing RF-negative from adult-type disease

Disease Heterogeneity

• Early-onset RF-negative polyarticular JIA (age 1–4 years) — resembles oligoarticular JIA that extended beyond 4 joints; ANA positive; higher uveitis risk; often milder disease severity
• Late-onset RF-negative polyarticular JIA (age 10–14 years) — more aggressive joint disease; symmetric small joint involvement; anti-CCP may be weakly positive in a subset; represents a transitional phenotype toward adult RA

RF-negative polyarticular JIA presents with symmetric or asymmetric arthritis of five or more joints, typically involving both large (knees, ankles, wrists) and small joints (MCPs, PIPs, MTPs). Morning stiffness lasting over 30 minutes is characteristic. Systemic features are absent or mild (low-grade fever only).

Joint Involvement

• Knees — almost universally involved; bilateral swelling with effusion; loss of full extension from flexion contracture if poorly controlled
• Wrists and hands (MCPs and PIPs) — bilateral symmetrical swelling; early wrist synovitis causes ulnar drift and volar subluxation in severe cases; PIP involvement more common than DIP
• Ankles and feet (MTPs) — common; hindfoot involvement causes altered gait; toe deformities in chronic disease
• Cervical spine — C2/C3 apophyseal joint involvement causing neck stiffness and limited rotation; atlanto-axial instability is a serious complication requiring MRI assessment before general anaesthesia
• Temporomandibular joints (TMJ) — common and frequently silent; asymmetric jaw involvement causes micrognathia (underdevelopment of mandible) if untreated; routine dental assessment recommended
• Hips — hip arthritis carries worse prognosis; associated with significant functional impairment; AVN risk with high-dose steroids

Systemic and Extra-Articular Features

• Low-grade fever — may accompany disease flares; high fever suggests systemic JIA overlap or intercurrent infection
• Uveitis — in ANA-positive patients (10–20% overall); typically asymptomatic chronic anterior uveitis; mandatory ophthalmological surveillance
• Growth failure — chronic inflammation suppresses growth hormone signalling; active disease and corticosteroid use both impair linear growth; catch-up growth occurs with disease control

Investigations confirm the diagnosis, classify uveitis risk, monitor disease activity, and screen for treatment toxicity. RF-negative polyarticular JIA is a clinical diagnosis; investigations exclude other causes of polyarthritis and confirm subtype.

• Essential
  Rheumatoid factor (RF) — ×2, ≥3 months apart

  Must be negative on two separate occasions at least 3 months apart to confirm RF-negative subtype. Positive RF on either occasion reclassifies to RF-positive polyarticular JIA, which has different prognosis and treatment implications. IgM RF (standard test); IgA RF positivity alone does not reclassify.
• Essential
  ANA (antinuclear antibody)

  Positive in 40–50% of RF-negative polyarticular JIA. Determines uveitis surveillance frequency. ANA titre ≥1:160 confers higher uveitis risk. Test at diagnosis; does not need repeating unless clinical change. Not diagnostic of JIA — low-titre ANA common in healthy children.
• Essential
  Anti-CCP antibodies

  Negative in RF-negative polyarticular JIA by definition. Anti-CCP positive status is associated with RF-positive disease. Weakly positive anti-CCP in an RF-negative child — reassess RF at 3–6 months; this may represent early RF-positive disease. Anti-CCP also negative in systemic JIA and ERA.
• Essential
  FBC, ESR, CRP, albumin

  Anaemia of chronic disease common in active disease. Thrombocytosis reflects inflammatory burden. ESR and CRP guide disease activity assessment and treatment response. Hypoalbuminaemia in severe/prolonged active disease. Ferritin — elevated in active disease; extremely high (>10,000 μg/L) raises concern for macrophage activation syndrome (consider systemic JIA).
• Essential
  Imaging of affected joints (X-ray ± MRI)

  Baseline X-ray of affected joints: periarticular osteopaenia, soft tissue swelling, growth disturbance. Joint space narrowing and erosions indicate structural damage — seek earlier in aggressive disease. MRI of wrists/hands: gold standard for detecting early erosions, synovitis, and tenosynovitis not visible on X-ray. Cervical spine MRI if neck stiffness or limited rotation — assess C2/C3 and atlanto-axial joint before anaesthesia.
• Recommended
  Ophthalmological slit-lamp assessment

  Indicated in all RF-negative polyarticular JIA patients with ANA positivity. Frequency based on ACR/AF 2019 risk stratification. ANA-negative RF-negative polyarticular JIA: every 12 months. ANA-positive with early onset: every 3–6 months. Any visual symptoms require urgent same-day ophthalmological assessment.

Disease activity in RF-negative polyarticular JIA is quantified using the Juvenile Arthritis Disease Activity Score (JADAS). Risk stratification guides treatment intensity and specialist referral urgency.

Treatment follows a stepwise approach: NSAIDs for symptom control, methotrexate as the anchor DMARD, and biologic therapy for MTX-refractory or severe disease. The goal is inactive disease (JADAS = 0) to prevent joint damage, uveitis complications, and growth failure.

Specific manifestations of RF-negative polyarticular JIA require directed management in addition to systemic DMARD therapy.

Intra-Articular Corticosteroid Injection (IAC)

• Triamcinolone hexacetonide (THK) — intra-articular injection of highly active joints while awaiting DMARD effect; knees, ankles, wrists, and small joints can all be injected
• Under general anaesthesia or conscious sedation in younger children — allows multiple joint injections in one setting
• NOT a substitute for systemic DMARD — polyarticular disease requires systemic treatment; IAC provides short-term joint control while DMARDs reach therapeutic effect

Uveitis Management

• Topical prednisolone acetate 1% eye drops — ophthalmologist-directed initial treatment for active uveitis; frequency guided by anterior chamber cell grading
• MTX — first-line systemic steroid-sparing agent for chronic uveitis; reduce topical steroid dependence
• Adalimumab — preferred biologic for uveitis refractory to MTX (SYCAMORE trial); do NOT use etanercept for uveitis (lacks ocular efficacy)

Corticosteroid Bridging

• Short-course oral prednisolone (0.3–0.5 mg/kg/day, max 20 mg) — for severe acute flare while awaiting DMARD/biologic effect; taper over 4–8 weeks
• IV methylprednisolone pulse — for severe disease flare; 10–30 mg/kg/day ×3 (max 1 g/day) in specialist inpatient setting; provides rapid anti-inflammatory effect
• Minimise systemic steroids — chronic steroid use causes growth suppression, osteoporosis, adrenal suppression, and obesity; lowest effective dose for shortest duration

Non-pharmacological interventions are integral to managing RF-negative polyarticular JIA, preserving function, and supporting the child’s development and quality of life.

Physiotherapy

• Range of motion and stretching — prevent joint contractures (especially knee, hip flexion contractures, wrist flexion contracture); daily stretching exercises essential during active disease
• Strengthening — quadriceps, hip abductor, and wrist extensor strengthening; muscle wasting is rapid with joint inflammation and immobility
• Hydrotherapy — warm water reduces pain and stiffness; buoyancy allows movement without joint loading; particularly useful for lower limb polyarthritis
• Splinting — resting splints for wrist and finger joints at night to prevent flexion contractures; serial casting for established contractures

Occupational Therapy

• Joint protection techniques — reduce load on inflamed joints; adaptive equipment (jar openers, writing aids) for hand involvement
• Footwear and orthotics — cushioned footwear for MTP and ankle involvement; custom insoles
• School accommodations — modified PE, rest periods, large-handle pencils, elevator access; formal letter to school from rheumatology team

Psychosocial Support

• Chronic illness adjustment — depression and anxiety are more prevalent in children with JIA; psychologist or social worker referral if significant psychosocial burden
• Family education — disease understanding, medication management, recognition of flares, importance of ophthalmology surveillance
• Peer support — Arthritis Australia and paediatric arthritis support groups provide peer connection for children and families

Monitoring in RF-negative polyarticular JIA encompasses disease activity assessment, treatment toxicity surveillance, growth monitoring, and uveitis surveillance.

When to Refer Urgently

• Suspected macrophage activation syndrome (MAS): Very high fever, hepatosplenomegaly, cytopenias, extremely elevated ferritin (>10,000 μg/L) — haematological emergency; urgent paediatric rheumatology and haematology
• Visual symptoms in JIA: Blurred vision, photophobia, or any visual change — urgent ophthalmology same day
• Neck stiffness before anaesthesia: Any child with JIA and limited cervical spine ROM — MRI before elective GA

Specific clinical scenarios in RF-negative polyarticular JIA require tailored management approaches.

Early-Onset (Age 1–4 Years)

• Resembles extended oligoarticular JIA — often ANA positive; higher uveitis risk; may have milder joint disease overall
• Diagnosis challenging — toddlers cannot articulate joint pain; presenting as irritability, limping, or refusal to use an arm
• Leukaemia exclusion — mandatory FBC and blood film; bone pain + cytopenias + lymphadenopathy → urgent bone marrow assessment

Late-Onset (Age 10–14 Years)

• More aggressive phenotype — symmetric small joint disease (hands and feet); resembles early adult RA; higher erosive risk
• Anti-CCP monitoring — if weakly anti-CCP positive, repeat RF at 3–6 months to detect evolving RF-positive disease
• Earlier biologic consideration — aggressive onset with structural changes warrants earlier escalation to biologic therapy

Transition to Adult Services

• ~50–70% of patients continue to have active disease at age 18; structured transition to adult rheumatology is essential
• Uveitis surveillance must continue in adult ophthalmology if risk factors present (ANA positive, prior uveitis) — risk does not disappear at age 18
• MTX contraception counselling — MTX is teratogenic; young women must be on effective contraception; discuss preconception planning with adult rheumatology at transition

Stewardship in RF-negative polyarticular JIA focuses on timely DMARD initiation, appropriate biologic selection, steroid minimisation, and ensuring infection and uveitis surveillance are not omitted.

GP Role in RF-Negative Polyarticular JIA

• Diagnosis trigger — arthritis persisting >6 weeks in 5 or more joints in a child under 16; exclude septic arthritis and ARF; urgent paediatric rheumatology referral
• Monitoring — FBC and LFTs monthly on MTX (first 3 months, then 3-monthly); growth monitoring 3–6 monthly; TB and HBV screening before biologics
• Uveitis facilitation — actively assist families in attending ophthalmology appointments; educate that JIA uveitis has no symptoms until late
• Immunisation — all age-appropriate vaccinations before biologic initiation; annual influenza vaccination; live vaccines contraindicated on biologics; document vaccination status

RF-negative polyarticular JIA requires long-term specialist follow-up for disease activity monitoring, treatment optimisation, uveitis surveillance, and growth monitoring. Approximately 30–50% achieve sustained remission by adulthood; others have active disease requiring ongoing treatment.

• 01
  Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778.
• 02
  Ringold S, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis. Arthritis Care Res. 2019;71(6):717–734.
• 03
  Ramanan AV, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis (SYCAMORE trial). Lancet. 2017;390(10103):1744–1755.
• 04
  Angeles-Han ST, et al. 2019 ACR/AF guideline for screening, monitoring, and treatment of JIA-associated uveitis. Arthritis Care Res. 2019;71(6):703–716.
• 05
  Petty RE, et al. ILAR classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
• 06
  Brunner HI, et al. Tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Lancet. 2015;385(9985):869–878.
• 07
  Therapeutic Guidelines. Rheumatology. Melbourne: Therapeutic Guidelines Ltd; 2024.
• 08
  Pharmaceutical Benefits Scheme (PBS). Schedule of Pharmaceutical Benefits. Canberra: Department of Health; 2025.